Meeting
2023 ASCO Gastrointestinal Cancers Symposium
Effect of dynamic circulating tumor DNA minimal residual disease detection on recurrence surveillance and second resection rate after curative intent resection of colorectal liver metastasis: A prospective cohort study.
Authors
Yaqi Li
Department of Colorectal Surgery, Fudan University Shanghai Cancer Center, Shanghai, China;
Yaqi Li , Jing Xu , Yikuan Chen , Xiaoji Ma , Xiang Hu , Yun Chen , Lei Sun , Huizi Wu , Zhihui Xiu , Qiduo Dong , Lin Chen , Jun Liu , Sanjun Cai , Junjie Peng
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Colorectal Cancer,Anal Cancer
Sub Track
Tumor Biology, Biomarkers, and Pathology
Clinical Trial Registration Number
ChiCTR2000035677
Citation
J Clin Oncol 41, 2023 (suppl 4; abstr 242)
DOI
10.1200/JCO.2023.41.4_suppl.242
Abstract #
242
Poster Bd #
N4
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Prediction of postoperative recurrence by integrating preoperative ctDNA levels and tumor metastasis volume in patients (pts) with colorectal cancer (CRC) with resectable lung or liver metastasis.
First Author: Hidekazu Oyoshi
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Association of pathologic nodal status with minimal residual disease after neoadjuvant treatment and resection of locally advanced rectal cancer.
First Author: Abhineet Uppal
Poster
2023 ASCO Annual Meeting
Association of positive ctDNA-based minimal residual disease assays during surveillance and undiagnosed concomitant radiographic recurrences in colorectal cancer (CRC): Results from the MD Anderson INTERCEPT program.
First Author: Arvind Dasari
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Optimising longitudinal plasma-only circulating tumour DNA (ctDNA) for minimal residual disease (MRD) detection with combined genomic/methylation signals to predict recurrence in patients (pts) with resected stage I-III colorectal cancer (CRC) in the UK multicentre prospective study TRACC.
First Author: Susanna Slater